Ultimovacs ASA - Poster presentation at the 2019 Annual Meeting of Society for Immunotherapy of Cancer (SITC)

 

Oslo, 30 October 2019: Ultimovacs ASA ("Ultimovacs" or "Company", ticker
ULTIMO), a pharmaceutical company developing novel immunotherapies against
cancer, announces that long-term results from a clinical study with UV1 in
Non-Small-Cell Lung Cancer will be presented during a poster session at the 2019
Annual Meeting of SITC. 

The SITC 34th Annual Meeting will be held in Maryland, USA, November 6-10, 2019.
The poster, named "Long term outcome of a Phase I Study with UV1, a
Second-Generation Telomerase Based Vaccine in Patients with advanced
Non-Small-Cell Lung Cancer", will be presented on 9 November. 

The Society for Immunotherapy of Cancer (SITC) is a professional society of
influential scientists, academicians, researchers, clinicians, government
representatives, and industry leaders from around the world dedicated to
improving cancer patient outcomes by advancing the science and application of
cancer immunotherapy. 

UV1 is a peptide-based vaccine inducing a specific T cell response against the
universal cancer antigen telomerase. UV1 is being developed as a therapeutic
cancer vaccine which may serve as a platform for use in combination with other
immuno-oncology drugs which require an ongoing T cell response for their mode of
action.

For further information, please see www.ultimovacs.com or contact:

Øyvind Kongstun Arnesen, CEO 
oeyvind.arnesen@ultimovacs.com, +47 469 33 810 

Hans Vassgård Eid, CFO 
hans.eid@ultimovacs.com, +47 469 19 822